STOCK TITAN
  1. Home
  2. Sec-filings
  3. RIGL
  4. [Form 4] RIGEL PHARMACEUTICALS INC Insider Trading Activity

Rigel Pharmaceuticals (RIGL) CEO exercises stock options, trims holdings

Filing Impact
(Very High)
Filing Sentiment
(Very Negative)
Form Type
4

Rhea-AI Filing Summary

Rigel Pharmaceuticals CEO Raul R. Rodriguez reported multiple insider stock transactions. On January 26, 2026, he exercised employee stock options in two 40,000-share lots at $27.40 per share and reported related dispositions of 35,211 and 35,424 common shares at $37 per share.

On February 2, 2026, he reported an additional disposition of 14,110 common shares at $36.01 per share. After these transactions, he directly beneficially owned 235,709 Rigel common shares, including 1,000 shares acquired under the company’s stock purchase plan. All share amounts reflect a one-for-ten reverse stock split effective June 27, 2024.

Positive

  • None.

Negative

  • None.
Insider RODRIGUEZ RAUL R
Role CEO, President
Type Security Shares Price Value
Tax Withholding Common Stock 14,110 $36.01 $508K
Exercise Employee Stock Option (right to buy) 40,000 $0.00 --
Exercise Employee Stock Option (right to buy) 40,000 $0.00 --
Exercise Common Stock 40,000 $27.40 $1.10M
Tax Withholding Common Stock 35,211 $37.00 $1.30M
Exercise Common Stock 40,000 $27.40 $1.10M
Tax Withholding Common Stock 35,424 $37.00 $1.31M
Holdings After Transaction: Common Stock — 235,709 shares (Direct); Employee Stock Option (right to buy) — 0 shares (Direct)
Footnotes (1)
  1. These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. Includes 1,000 shares acquired under the Issuer's stock purchase plan. The shares vested monthly over two (2) years from January 1, 2016.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
RODRIGUEZ RAUL R
(Last) (First) (Middle)
RIGEL PHARMACEUTICALS, INC.
611 GATEWAY BLVD, SUITE 900
(Street)
SOUTH SAN FRANCISCO CA 94080
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
RIGEL PHARMACEUTICALS INC [ RIGL ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
CEO, President
3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/26/2026 M 40,000(1) A $27.4(1) 280,454(2) D
Common Stock 01/26/2026 F 35,211 D $37 245,243 D
Common Stock 01/26/2026 M 40,000(1) A $27.4(1) 285,243 D
Common Stock 01/26/2026 F 35,424 D $37 249,819 D
Common Stock 02/02/2026 F 14,110 D $36.01 235,709 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy) $27.4(1) 01/26/2026 M 40,000(1) (3) 01/26/2026 Common Stock 40,000(1) $0 0 D
Employee Stock Option (right to buy) $27.4(1) 01/26/2026 M 40,000(1) 04/19/2017 01/26/2026 Common Stock 40,000(1) $0 0 D
Explanation of Responses:
1. These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.
2. Includes 1,000 shares acquired under the Issuer's stock purchase plan.
3. The shares vested monthly over two (2) years from January 1, 2016.
/s/ Raymond Furey (Attorney-in-Fact) 02/04/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did RIGL CEO Raul R. Rodriguez report?

Raul R. Rodriguez reported option exercises and share dispositions. On January 26, 2026, he exercised two 40,000-share employee stock options and reported related common stock dispositions. On February 2, 2026, he reported another disposition of 14,110 common shares at $36.01 per share.

How many Rigel (RIGL) shares does Raul Rodriguez own after these trades?

After the reported transactions, Raul Rodriguez owned 235,709 shares. The filing shows he directly beneficially owned 235,709 Rigel common shares, which includes 1,000 shares acquired under the issuer’s stock purchase plan, with all figures adjusted for the prior reverse stock split.

At what prices were Raul Rodriguez’s Rigel common stock transactions reported?

The filing lists prices of $27.40, $37, and $36.01 per share. Option exercises on January 26, 2026 used a $27.40 exercise price, while common stock dispositions that day were reported at $37. A later disposition on February 2, 2026 was reported at $36.01 per share.

What role did employee stock options play in this Rigel (RIGL) Form 4?

Rodriguez exercised employee stock options for common shares. On January 26, 2026, he exercised employee stock options described as rights to buy 40,000-share lots of common stock at $27.40 per share, and those specific option positions were reported as having zero derivative securities remaining afterward.

How did Rigel’s reverse stock split affect the share numbers in this Form 4?

All reported share amounts reflect a one-for-ten reverse split. A footnote explains that the numbers have been adjusted for Rigel’s one-for-ten reverse stock split that became effective on June 27, 2024, so the reported holdings and transaction sizes use post-split figures.

What types of securities are reported in Raul Rodriguez’s Rigel (RIGL) Form 4?

The Form 4 reports common stock and employee stock options. Table I covers transactions in Rigel common stock, while Table II discloses exercises of employee stock options described as rights to buy common shares at a $27.40 exercise price, with those option positions reduced to zero afterward.